Sustained release of brimonidine from conjunctival sac insert to reduce intraocular pressure for glaucoma treatment.

The conjunctival sac insert (BRI@SR@PT), as a promising drug-delivery platform, may provide a sustained IOP-lowering treatment for patients with ocular hypertension or glaucoma, without the need for invasive procedures.